AYTU BIOPHARMA, INC. - 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed on December 19, 2017, regarding events occurring on December 18, 2017. The filing discloses the appointment of a new Chief Financial Officer and the execution of a material definitive employment agreement.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and employment terms.
Material Changes
- Executive Departure: Gregory A. Gould resigned as Chief Financial Officer effective November 15, 2017.
- Executive Appointment: David A. Green was appointed Chief Financial Officer, Secretary, and Treasurer effective December 18, 2017.
- Compensation Structure: Mr. Green's employment agreement establishes a base salary of $250,000 annually with a discretionary bonus of up to 50% of base salary.
- Equity Grant: The Company agreed to grant 75,000 restricted shares of common stock on or promptly after January 1, 2018.
Outlook, Risks, and Unusual Items
The filing details termination provisions and change of control arrangements:
- Termination Benefits: In the event of termination without Cause, Disability, or resignation for Good Reason, Mr. Green is entitled to accrued compensation, a lump sum equal to 100% of his base salary, and up to 12 months of health and welfare plan participation.
- Change of Control: All stock options, restricted stock, and other stock-based grants will immediately and irrevocably vest upon a Change of Control.
- Risk Factors: No specific financial risks or contingencies are disclosed in this filing.
Investor Verification Checklist
- Verify the vesting schedule and specific terms of the 75,000 restricted shares granted to Mr. Green.
- Review the full text of the Employment Agreement (Exhibit 10.1) for definitions of "Cause," "Good Reason," and "Disability."
- Confirm the impact of the CFO transition on the Company's financial reporting timeline and internal controls.
- Check subsequent filings for the actual issuance date of the restricted stock.